Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial

By sjmartinez • February 16, 2024

Szlosarek PW, Creelan BC, Sarkodie T, Nolan L, Taylor P, Olevsky O, Grosso F, Cortinovis D, Chitnis M, Roy A, Gilligan D, Kindler H, Papadatos-Pastos D, Ceresoli GL, Mansfield AS, Tsao A, O'Byrne KJ, Nowak AK, Steele J, Sheaff M, Shiu CF, Kuo CL, Johnston A, Bomalaski J, Zauderer MG, Fennell DA; ATOMIC-Meso Study Group. Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial. JAMA Oncol. 2024 Feb 15. doi: 10.1001/jamaoncol.2023.6789. Epub ahead of print. PMID: 38358753.

Tags: Hematology/Oncology, Publications

Related Posts

The evolving role of ctDNA in colorectal cancer: guidance of adjuvant therapy or surveillance strategies?

Barrett LG, Gangi A, Hendifar A, Osipov A, Atkins K, Zaghiyan K, Nasseri Y, Murrell Z, Waters K, Mehta P, Zell JA, Hitchins MP, Gong[...]

Microbiome Signatures in Advanced Gastric Cancer: Emerging Biomarkers for Risk Stratification, Therapy Guidance, and Prognostic Insight

Kim KJ, Zhong H, Tai D, Shah P, Park D, Goes V, Li J, Jung C, Kim L, Guzman S, Brar G, Castillo D. Microbiome[...]

ASH 2026 Guidelines for Management of Relapsed/Refractory Disease in Adolescents and Young Adults with ALL

O'Dwyer KM, Winestone LE, Cheung MC, Benitez L, Buldini B, Cole PD, Damlaj M, Dholaria B, Dias AL, Dils A, Fritsch M, Greer JP, Hayes-Lattin[...]